MWVC
MRVI icon

Morgens Waterfall Vintiadis & Co’s Maravai LifeSciences MRVI Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38,000
Closed -$1.59M – 33
2021
Q4 		$1.59M Buy
+38,000
New +$1.54M 0.86% 26

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's MRVI Position: Q1 2022 in Review

Morgens Waterfall Vintiadis & Co sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 38,000 shares — an estimated $1.59M sold.

Morgens Waterfall Vintiadis & Co first reported a position in MRVI in Q4 2021 and held it in 1 quarter. The position peaked at $1.59M in Q4 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

  • Morgens Waterfall Vintiadis & Co reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 38,000 Maravai LifeSciences shares in Q1 2022, an estimated $1.59M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Maravai LifeSciences in Q4 2021 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Maravai LifeSciences position peaked at $1.59M in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2022, filed 16 May 2022.